Tirzepatide just got a second FDA approval: cutting cardiovascular risk

What the FDA approved, and who it covers

On August 28, 2026, the FDA cleared a new indication for Mounjaro, Eli Lilly's brand name for tirzepatide: reducing the risk of major adverse cardiovascular events, cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes who are already at high risk for one of those events. Lilly is marketing tirzepatide as the first and only dual GIP/GLP-1 drug to carry that specific claim. The indication sits on top of Mounjaro's existing approval for blood sugar control. It does not touch Zepbound, the identical molecule sold under a different name for weight management in people without diabetes, because the trial behind it only enrolled patients with type 2 diabetes.

Practically, this is a label change, not a new drug, dose, or delivery device. Doctors who already prescribe tirzepatide for type 2 diabetes can now point to FDA-recognized trial evidence that it also lowers cardiovascular risk, which may shift how it gets positioned against other diabetes drugs for patients with existing heart disease. It does not require current patients to do anything differently.

What is the SURPASS-CVOT trial?

The approval is built on SURPASS-CVOT (NCT04255433), an event-driven, randomized, double-blind Phase 3 trial that enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 640 sites in 30 countries. It ran for a median follow-up of 210.1 weeks, close to four years, inside a trial designed to run about five years overall. That makes it the largest and longest tirzepatide study completed to date, dwarfing the SURMOUNT and SURPASS trials that established the drug's weight-loss and glucose-lowering effects.

The design choice that sets SURPASS-CVOT apart is the comparator. Instead of testing tirzepatide against a placebo, Lilly tested it head-to-head against dulaglutide, sold as Trulicity, a GLP-1 receptor agonist with its own established cardiovascular benefit from earlier trials. Participants took either tirzepatide at 15mg or their maximum tolerated dose, or dulaglutide at 1.5mg, both weekly injections, for the length of the study.

What the trial actually found

Tirzepatide produced an 8% lower rate of the combined endpoint, cardiovascular death, non-fatal heart attack, or non-fatal stroke, than dulaglutide. The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. That result cleared the trial's pre-specified bar for non-inferiority. It did not clear the separate, harder bar for statistical superiority, since the confidence interval crosses 1.0. In plain terms: tirzepatide protects against heart attack, stroke, and cardiovascular death at least as well as a drug already proven to do so. The data do not support a claim that it does better.

Safety findings tracked what tirzepatide's label already discloses. The most common side effects were gastrointestinal, nausea, diarrhea, and vomiting, mild to moderate in severity and concentrated during the early dose-escalation period. Lilly did not report new safety signals distinct from the drug's existing profile across its weight-loss and diabetes trials.

Why test against a proven drug instead of a placebo?

Testing a new drug against a placebo is the faster, cheaper way to prove it works. Testing it against a drug that already has FDA-recognized heart benefits is a harder, more expensive bet, because merely tying the comparator counts as a real result rather than a given. Lilly's own framing of SURPASS-CVOT leans into that: the company is presenting the head-to-head design itself as evidence of confidence in tirzepatide's cardiovascular profile, not just its weight-loss numbers. Regulatory filings based on the same trial data are also under review in other markets, and the results are already reflected in Mounjaro's European product information.

How this compares to semaglutide's own heart-health approval

Tirzepatide is not the first GLP-1-class drug to carry a cardiovascular claim in type 2 diabetes. Semaglutide got there first, most recently through the SOUL trial, which found oral semaglutide cut major adverse cardiovascular events 14% against a placebo in more than 9,600 high-risk patients. The two trials are not a fair head-to-head against each other, because one tested against a placebo and the other against an active drug that already had its own proven benefit, a much higher bar to clear.

Read the full numbers behind semaglutide's own result in our breakdown of the SOUL trial. The practical takeaway for patients is not which drug wins on paper. It is that two of the biggest diabetes drugs on the market now have FDA-recognized evidence that they lower cardiovascular risk on top of managing blood sugar, which was not true for either drug a few years ago.

What changes for patients already on tirzepatide

For most people already taking Mounjaro or Zepbound, the honest answer is: not much, immediately. Dosing, injection schedule, and price are unchanged. Patients do not need a new prescription or a conversation with their doctor unless they want one. Where it could matter is for people with type 2 diabetes and existing heart disease who have not yet started a GLP-1 drug. That population is exactly who SURPASS-CVOT enrolled, and doctors now have a specific, FDA-approved reason to consider tirzepatide over an older diabetes drug without a cardiovascular claim.

The approval also does not change what tirzepatide costs. Zepbound still runs $299 to $449 a month through Lilly's self-pay program depending on dose, and the Medicare GLP-1 Bridge still brings eligible patients to $50 a month. For the full breakdown of every pricing route, see our tirzepatide cost guide. If you are shopping for a GLP-1 program rather than pricing an existing prescription, our comparison of the top GLP-1 programs covers how tirzepatide access typically works through telehealth.

What to watch next

Tirzepatide's cardiovascular data is arriving alongside a broader wave of trial results for the drug this year, including its generic competition still years away, covered in our tirzepatide patent timeline. Two open questions are worth tracking. First, whether Lilly seeks a matching cardiovascular indication for Zepbound in people with obesity but not diabetes, which would need its own trial in that population. Second, whether other incretin drugs still in development, including retatrutide, run their own head-to-head cardiovascular outcomes trials rather than placebo-controlled ones, now that Lilly has shown the harder trial design is winnable.